Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.
IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2
申请人:Incyte Corporation
公开号:EP3898627A1
公开(公告)日:2021-10-27
US8946222B2
申请人:——
公开号:US8946222B2
公开(公告)日:2015-02-03
[EN] IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2<br/>[FR] COMPOSÉS D'IMIDAZOPYRIDAZINE ET D'IMIDAZOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE 2 DE TYPE RÉCEPTEUR DE L'ACTIVINE
申请人:INCYTE CORP
公开号:WO2020132197A1
公开(公告)日:2020-06-25
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
申请人:Incyte Corporation
公开号:US20200199131A1
公开(公告)日:2020-06-25
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.